| 1 Dichotomous outcomes for acute participants |
7 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1 Leaving the study early: 1. Any reason |
7 |
447 |
Risk Ratio (M‐H, Random, 95% CI) |
1.25 [1.06, 1.47] |
| 1.2 Leaving the study early: 2. Due to adverse events |
3 |
314 |
Risk Ratio (M‐H, Random, 95% CI) |
1.55 [0.72, 3.34] |
| 1.3 Leaving the study early: 3. Due to relapse/ worsening or no improvement |
2 |
129 |
Risk Ratio (M‐H, Random, 95% CI) |
1.46 [0.34, 6.26] |
| 1.4 Global state: 1. Change over time ‐ no better or deterioration |
5 |
240 |
Risk Ratio (M‐H, Random, 95% CI) |
0.87 [0.27, 2.82] |
| 1.5 Mental state: 1. State ‐ less than 20% BPRS reduction ('no effect') |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.81 [0.61, 1.08] |
| 1.6 Mental state: 2. State ‐ less than 20% PANSS reduction ('no effect') |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.86 [0.64, 1.15] |
| 1.7 Adverse events: 1. Movement disorders ‐ dystonia |
2 |
129 |
Risk Ratio (M‐H, Random, 95% CI) |
1.11 [0.12, 10.02] |
| 1.8 Adverse events: 2. Movement disorders ‐ extrapyramidal signs |
1 |
22 |
Risk Ratio (M‐H, Random, 95% CI) |
0.86 [0.39, 1.88] |
| 1.9 Adverse events: 3. Movement disorders ‐ use of antiparkinson drugs |
2 |
129 |
Risk Ratio (M‐H, Random, 95% CI) |
1.07 [0.65, 1.76] |
| 1.10 Adverse events: 4. Movement disorders ‐ hyperkinesia |
2 |
135 |
Risk Ratio (M‐H, Random, 95% CI) |
2.64 [0.88, 7.91] |
| 1.11 Other adverse events: 5. Anticholinergic ‐ dry mouth |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
7.40 [0.39, 139.81] |
| 1.12 Other adverse events: 6. Arousal ‐ drowsiness |
2 |
50 |
Risk Ratio (M‐H, Random, 95% CI) |
1.01 [0.12, 8.33] |
| 1.13 Other adverse events: 7. Arousal ‐ insomnia |
2 |
161 |
Risk Ratio (M‐H, Random, 95% CI) |
0.84 [0.16, 4.50] |
| 1.14 Other adverse events: 8. Arousal ‐ need of additional benzodiazepines |
1 |
17 |
Risk Ratio (M‐H, Random, 95% CI) |
0.71 [0.35, 1.46] |
| 1.15 Other adverse events: 9. Arousal ‐ sleepiness/sedation |
2 |
161 |
Risk Ratio (M‐H, Random, 95% CI) |
1.19 [0.71, 2.00] |
| 1.16 Other adverse events: 10. Arousal ‐ tension |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.97 [0.63, 1.50] |
| 1.17 Other adverse events: 11. At least one |
3 |
157 |
Risk Ratio (M‐H, Random, 95% CI) |
1.04 [0.88, 1.23] |
| 1.18 Other adverse events: 12. Cardiovascular ‐ faintness, dizziness, weakness |
2 |
161 |
Risk Ratio (M‐H, Random, 95% CI) |
1.12 [0.54, 2.33] |
| 1.19 Other adverse events: 13. Cardiovascular ‐ lassitude |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.97 [0.61, 1.52] |
| 1.20 Other adverse events: 14. Cardiovascular ‐ tachycardia |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.57 [0.25, 1.32] |
| 1.21 Other adverse events: 15. Central nervous system ‐ difficulty in concentration |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
1.06 [0.71, 1.58] |
| 1.22 Other adverse events: 16. Central nervous system ‐ headache |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.53 [0.14, 2.01] |
| 1.23 Other adverse events: 17. Central nervous system ‐ paraesthesia |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.71 [0.12, 4.05] |
| 1.24 Other adverse events: 18. Gastrointestinal ‐ constipation |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.07 [0.00, 1.20] |
| 1.25 Other adverse events: 19. Gastrointestinal ‐ diarrhoea |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.15 [0.01, 2.85] |
| 1.26 Other adverse events: 20. Gastrointestinal ‐ nausea and vomiting |
2 |
154 |
Risk Ratio (M‐H, Random, 95% CI) |
0.64 [0.24, 1.68] |
| 1.27 Other adverse events: 21. Gastrointestinal ‐ weight loss |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
2.12 [0.56, 8.02] |
| 1.28 Other adverse events: 22. Gastrointestinal ‐ weight gain |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.50 [0.26, 0.97] |
| 1.29 Other adverse events: 23. Skin ‐ pruritus |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.79 [0.19, 3.38] |
| 1.30 Other adverse events: 24. Skin ‐ rash |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.71 [0.12, 4.05] |
| 1.31 Other adverse events: 25. Skin ‐ sweating |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.66 [0.23, 1.89] |
| 1.32 Other adverse events: 26. Genitourinary ‐ diminished sexual desire |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
1.06 [0.22, 5.01] |
| 1.33 Other adverse events: 27. Genitourinary ‐ ejaculatory dysfunction (men only) |
1 |
77 |
Risk Ratio (M‐H, Random, 95% CI) |
0.18 [0.02, 1.43] |
| 1.34 Other adverse events: 28. Genitourinary ‐ erectile dysfunction (men only) |
1 |
77 |
Risk Ratio (M‐H, Random, 95% CI) |
0.90 [0.30, 2.70] |
| 1.35 Other adverse events: 29. Genitourinary ‐ galactorrhoea |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.15 [0.01, 2.85] |
| 1.36 Other adverse events: 30. Genitourinary ‐ increased sexual desire |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
1.06 [0.22, 5.01] |
| 1.37 Other adverse events: 31. Genitourinary ‐ orgastic dysfunction |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
5.28 [0.26, 107.51] |
| 1.38 Other adverse events: 32. Others ‐ abdominal pain |
1 |
47 |
Risk Ratio (M‐H, Random, 95% CI) |
0.14 [0.01, 2.52] |
| 1.39 Other adverse events: 33. Others ‐ failing memory |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
1.27 [0.60, 2.68] |
| 1.40 Other adverse events: 34. Others ‐ sweating |
1 |
107 |
Risk Ratio (M‐H, Random, 95% CI) |
0.96 [0.45, 2.07] |
| 2 Continuous outcomes for acute participants |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 2.1 Mental state: 1. State ‐ PANSS: mean change from baseline to endpoint |
1 |
107 |
Mean Difference (IV, Random, 95% CI) |
4.0 [‐5.04, 13.04] |
